Home Physical Sciences Crystal structure of 1-(4-chlorophenyl)-6,8-diphenyl-1H-pyrazolo[4,3-c]quinoline, C28H18ClN3
Article Open Access

Crystal structure of 1-(4-chlorophenyl)-6,8-diphenyl-1H-pyrazolo[4,3-c]quinoline, C28H18ClN3

  • Marole M. Maluleka and Malose J. Mphahlele EMAIL logo
Published/Copyright: February 10, 2017

Abstract

C28H18ClN3, monoclinic, P21/c, (no. 14) a = 5.9519(2) Å, b = 8.0511(3) Å, c = 43.4071(14) Å, β = 90.001(2)°, V =2080.04(12) Å3, Z = 4, Rgt(F) = 0.066, wRref(F2) = 0.190, T = 173 K.

CCDC no.:: 1433469

Tables 1 and 2 contain details on crystal structure and measurement conditions and a list of the atoms including atomic coordinates and displacement parameters.

Table 1

Data collection and handling.

Crystal:Colorless rod
Size:0.47 × 0.19 × 0.04 mm
Wavelength:Mo Kα radiation (0.71073 Å)
μ:0.206 mm−1
Diffractometer, scan mode:Bruker D8 Venture, ω (0.5° width)
θmax, completeness:25.49°, 96%
N(hkl)measured, N(hkl)unique, Rint:10748,3720, 0.0980
Criterion for Iobs, N(hkl)gt:Iobs > 2 σ(Iobs), 3009
N(param)refined:290
Programs:XPREP [2], WinGX [4], SHELXS [3]
Table 2

Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2).

AtomxyzUiso*/Ueq
C10.7902(7)0.5667(5)0.10136(10)0.0326(9)
C20.8760(9)0.5319(5)0.07259(10)0.0398(10)
H21.01690.47770.07040.048*
C30.7519(9)0.5778(6)0.04686(11)0.0432(11)
H30.80820.55680.02680.052*
C40.5448(8)0.6546(6)0.05075(11)0.0409(11)
C50.4628(8)0.6884(5)0.07956(11)0.0406(11)
H50.32060.74060.08180.049*
C60.5849(8)0.6470(5)0.10514(11)0.0375(10)
H60.53040.67270.12520.045*
C71.1560(8)0.5054(6)0.16335(10)0.0395(10)
H71.28330.53280.17560.047*
C81.0106(8)0.3707(5)0.16969(10)0.0326(9)
C90.9907(8)0.2425(5)0.19190(10)0.0334(9)
H91.09710.23990.20820.040*
C100.6785(7)0.1312(5)0.16763(9)0.0293(9)
C110.6773(7)0.2527(5)0.14389(9)0.0302(9)
C120.8507(7)0.3747(5)0.14645(9)0.0317(9)
C130.5199(7)0.2438(5)0.11996(9)0.0307(9)
H130.51980.32690.10440.037*
C140.3657(7)0.1171(5)0.11852(9)0.0297(9)
C150.3600(7)−0.0006(5)0.14265(9)0.0301(9)
H150.2485−0.08500.14240.036*
C160.5144(7)0.0044(5)0.16673(9)0.0296(9)
C170.2097(7)0.1035(5)0.09169(9)0.0286(9)
C180.2744(8)0.1631(5)0.06268(10)0.0338(10)
H180.41700.21450.06030.041*
C190.1340(9)0.1483(5)0.03749(10)0.0401(11)
H190.18100.18800.01790.048*
C20−0.0772(8)0.0748(6)0.04083(11)0.0420(11)
H20−0.17530.06500.02370.050*
C21−0.1407(8)0.0171(5)0.06916(10)0.0384(10)
H21−0.2847−0.03210.07160.046*
C220.0019(8)0.0292(5)0.09456(10)0.0360(10)
H22−0.0443−0.01390.11390.043*
C230.4975(7)−0.1273(5)0.19095(9)0.0300(9)

Source of material

The title compound was previously prepared by the reaction of 6,8-dibromo-4-chloroquinoline-3-carbaldehyde with 4-chlorophenylhydrazine hydrochloride (1.5 equiv.) in ethanol in the presence of triethylamine (1.5 equiv.) to afford the corresponding (6,8-dibromo-4-chloroquinolin-3-yl)methylene]-2-(4-chlorophenyl)hydrazide. This hydrazide derivative was, in turn, cyclized with ethanolic KOH (5% in ethanol) to afford the corresponding 6,8-dibromo-1-(2-chlorophenyl)-1H-pyrazolo[4,3-c]quinoline. The 1,6,8-triaryl-1H-pyrazolo[4,3-c]quinoline used in this investigation was prepared via Suzuki-Miyaura cross-coupling of the corresponding 1-aryl-6,8-dibromo-1H-pyrazolo[4,3-c]quinoline with arylboronic acids [1]. Crystals of the title compound were obtained by recrystallization in dimethylformamide.

Experimental details

Data reduction was carried out using SAINT+ software, and SADABS was used to make empirical absorption corrections [2]. The crystal structure was solved through direct methods using SHELXS-97 [3]. Hydrogen atoms were positioned geometrically and allowed to ride on their respective parent atoms with d(C–H) = 0.95 Å and Uiso(H) = 1.2Ueq(C). Diagrams and publication material were generated using WinGX [4] and PLATON [5].

Discussion

In recent years there has been growing interest in the design and synthesis of pyrazolo[4,3-c]quinoline-based compounds [6] due to their wide-range of biological properties. Pyrazolo[4,3-c]quinoline derivatives serve as photosensitizing anti-cancer agents [7], benzodiazepine antagonists [8], selective cyclooxygenase-2 (COX-2) inhibitors [9] and others exhibit anti-inflammatory properties [6]. Interest in pyrazolo[4,3-c]quinoline-based compounds is not only limited to the synthesis or development of more diverse and complex bioactive derivatives for structure-activity relationship evaluations, but has since been extended to focus on their photophysical properties as potential photosensitizing anti-cancer agents and fluorescence probes. The crystallographic study of the 1-(4-chlorophenyl)-6,8-diphenyl-1H-pyrazolo[4,3-c]quinolone was carried out to determine its molecular structure and the geometry of the pyrazolo[4,3-c]quinoline tricyclic system. The 1-aryl ring is highly deformed out of plane of the pyrazoloquinazoline framework (average torsion angle ca. 75.2°) compared to other aryl substituents to avoid steric interaction between its ortho-hydrogen atoms and H-9 (C13). The slight twist of the 6-aryl ring from co-planarity (average torsion angle ca. −59.2°), on the other hand, minimizes steric interaction between its ortho-hydrogen atoms on C24 and C28 with the lone pair electrons on N3 and C15, respectively.

Acknowledgement

The authors are grateful to the University of South Africa and the National Research Foundation for financial assistance.

References

1 Maluleka, M. M.; Mphahlele, M. J.: 6,8-Dibromo-4-chloroquinoline-3-carbaldehyde as a synthon in the development of novel 1,6,8-triaryl-1H-pyrazolo[4,3-c]quinolones. Tetrahedron 69 (2013) 699–704.10.1016/j.tet.2012.10.103Search in Google Scholar

2 Bruker: SAINT-Plus and SADABS. Bruker AXS Inc., Madison, Wisconsin, USA, 2004.Search in Google Scholar

3 Sheldrick, G. M.: A Short History of SHELX. Acta Crystallogr. A64 (2008) 112–122.10.1107/S0108767307043930Search in Google Scholar PubMed

4 Farrugia, L. J.: WinGX suite for small-molecule single-crystal crystallography. J. Appl. Cryst. 32 (1999) 837–838.10.1107/S0021889899006020Search in Google Scholar

5 Spek, A. L.: Structure validation in chemical crystallography. Acta Crystallogr. D65 (2009) 148–155.10.1107/S090744490804362XSearch in Google Scholar PubMed PubMed Central

6 Mekheimer, R. A.; Ahmed, E. A.; Sadek, K. U.: Recent developments in the chemistry of pyrazolo[4,3-c]quinolones. Tetrahedron 68 (2012) 1637–1667.10.1016/j.tet.2011.10.088Search in Google Scholar

7 Wang, C.; Tang, C.; Li, Z.; Wang, Q.: Palladium-catalyzed synthesis of 1H-pyrazolo[4,3-c]quinolines and 4-anilinoquinoline-3-carbonitriles from 4-chloroquinoline-3-carbaldehydes. Synthesis 47 (2015) 3139–3146.10.1055/s-0034-1381010Search in Google Scholar

8 Spano, V.; Parrino, B.; Carbone, A.; Montalbano, A.; Salvador, A.; Brun, P.; Vedaldi, D.; Diana, P.; Cirrincione, G.; Barraja, P.: Pyrazolo [3, 4-h] quinolines: promising photosensitizing agents in the treatment of cancer. Eur. J. Med. Chem. 102 (2015) 334–351.10.1016/j.ejmech.2015.08.003Search in Google Scholar PubMed

9 Baraldi, P. G.; Tabrizi, M. A.; Preti, D.; Bovero, A.; Fruttarolo, F.; Romagnoli, R.; Zaid, N. A.; Moorman, A. R.; Varani, K.; Borea, P. A.: New 2-arylpyrazolo [4, 3-c] quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. J. Med. Chem. 48 (2005) 5001–5008.10.1021/jm050125kSearch in Google Scholar PubMed

Received: 2016-8-1
Accepted: 2017-1-13
Published Online: 2017-2-10
Published in Print: 2017-3-1

©2017 Marole M. Maluleka et al., published by De Gruyter.

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Articles in the same Issue

  1. Cover and Frontmatter
  2. The crystal structure of triphenylphosphineoxide – 2,5-dichloro-3,6-dihydroxycyclohexa-2,5-diene-1,4-dione (2/1), C42H32Cl2O6P2
  3. Crystal structure of poly-[diaqua-[bis(μ2-hydroxy)-bis(μ4-3,4,5,6-tetrachlorophthalato-κ3O,O′:O′; κ2O′′:O′′′)dilanthanum(III)], C8H3Cl4LaO6
  4. Crystal structure of 1,1′-(3,4-diphenylthieno[2,3-b]thiophene-2,5-diyl)bis[1-phenyl-methanone], C32H20O2S2
  5. Crystal structure of 4a-hydroxy-9-(3,5-dibromo-phenyl)-3,4,4a,5,6,7,9,9a-octahydro-2H-xanthene-1,8-dione, C19H18Br2O4
  6. Crystal structure of 5-hydroxy-4,6,9,10-tetramethyl-1-oxo-6-vinyldecahydro-3a,9-propanocyclopenta[8]annulen-8-yl 2-((2-methyl-1-(3-methylbenzamido)propan-2-yl)thio)acetate, C34H49NO5S
  7. Crystal structure of pyridinium bis(naphthalane-2,3-diolato-κ2O,O′)borate monohydrate, C25H20BNO5
  8. Crystal structure of 1,1′-((1E,1′E)-(((ethane-1,2-diylbis(oxy))bis(2,1-phenylene))bis(azanylylidene))bis(methanylylidene))bis(naphthalen-2-olato)nickel(II), C72H52N4O8Ni2
  9. The crystal structure of 3-(2-acetyl-4-butyramido-phenoxy)-2-hydroxy-N-isopropylpropan-1-aminium tetraphenylborate, C42H49BN2O4
  10. Crystal structure of 4-bromobenzyl (Z)-N′-(adamantan-1-yl)-4-phenylpiperazine-1-carbothioimidate, C28H34BrN3S
  11. Crystal structure of poly-[(μ6-benzene-1,2,4,5-tetracarboxylato)-(μ2-1,2-bis(imidazol-1-ylmethyl)benzene)dicobalt(II)], Co2C24H16N4O8
  12. Crystal structure of catena-(bis(μ2-1, 2-bis(imidazole-1-ylmethyl)benzene-κN:N′)-dichlororido-nickel(II)), C28H28Cl2N8Ni
  13. Crystal structure of (Z)-1-(1,5-dimethyl-1H-pyrazol-3-yl)-3-hydroxy-3-(4-methoxyphenyl)prop-2-en-1-one, C15H16N2O3
  14. Crystal structure of (Z)-1-(1,5-dimethyl-1H-pyrazol-3-yl)-3-hydroxy-3-phenylprop-2-en-1-one, C14H14N2O2
  15. Crystal structure of (E)-2-(4-hydroxy-3-methoxybenzylidene)-6-methoxy-3,4-dihydronaphthalen-1(2H)-one, C19H18O4
  16. Crystal structure of (Z)-1-(1,5-dimethyl-1H-pyrazol-3-yl)-3-(4-ethoxyphenyl)-3-hydroxyprop-2-en-1-one, C16H18N2O3
  17. Crystal structure of (Z)-1-(1,5-dimethyl-1H-pyrazol-3-yl)-3-hydroxy-3-(p-toly)prop-2-en-1-one, C15H16N2O2
  18. Crystal structure of 1-acetyl-3-(3-chlorophenyl)-5-(4-isopropylphenyl)-4,5-dihydro-(1H)-pyrazole, C20H21ClN2O
  19. The crystal structure of 1-methyl-2,4-dinitro-5-iodoimidazole, C4H3IN4O4
  20. The crystal structure of 4-chloro-3,5-dinitroaniline, C6H4ClN3O4
  21. Crystal structure of N,N-dimethyl-N′-(2-methyl-4-oxo-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-3(4H)-yl)formimidamide, C14H18N4OS
  22. Crystal structure of tetrakis(μ2-acetato-κ2O:O′)-bis[μ3-4-chloro-2,6-bis((methylimino)methyl)phenolato-κ2N,O:O,N′]-(μ4-oxido)tetracopper(II), C28H32Cl2Cu4N4O11
  23. Crystal structure of catena-poly[diaqua-bis(μ2-ethane-1,2-diyl-bis(pyridine-3-carboxylate-κ2N:N′))copper(II)] dinitrate, C28H28CuN6O16
  24. Synthesis and crystal structure of catena-poly[(μ2-nicotinato-κ2O,O′: κ1N)-(nitrato-κ1O)-(bis(2-benzimidazol-ylmethyl)amine-κ3N,N′,N′′)lead(II)], C22H18N7O5Pb
  25. The twinned crystal structure of (4SR)-7-benzyl-2,4,8,8-tetramethyl-7,8-dihydroimidazo[5,1-c][1,2,4]triazine-3,6(2H,4H)-dione, C16H20N4O2
  26. Crystal structure of (Z)-3-hydroxy-3-(4-methoxyphenyl)-1-(pyridin-2-yl)prop-2-en-1-one, C15H13NO3
  27. Crystal structure of 2-amino-4-(2,3-dichlorophenyl)-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile, C16H12Cl2N2O2
  28. Crystal structure of catena-poly[(μ2-butane-1,4-diyl-bis(pyridine-3-carboxylato-κN))silver(I)] tetrafluoroborate, C16H16AgN2O4BF4
  29. Crystal structure of poly[diaqua-(1,10-phenanthroline-κ2N,N′)-(μ2-2,5-dihydroxytere-phthalato)-bis(μ4-2,5-dihydroxyterephthalato)dicerium(III)], C24H16CeN2O10
  30. Crystal structure of 5,7,4′-trihydroxy-3,8,3′-trymethoxyflavone, C18H16O8
  31. Crystal structure of N-(3,4-dichlorobenzylidene)-4-methylaniline, C14H11Cl2N
  32. Crystal structure of 4-(3-Methoxy-phenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydro-quinoline-3-carboxylic acid ethyl ester, C22H27NO4
  33. Crystal structure of 2-amino-4-(3-fluorophenyl)-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile, C16H13FN2O2
  34. Crystal structure of 1,1,(3,4-dihydroxythieno[2,3-b] thiophene-2,5-diyl)bis(2-bromoethanone), C10H6Br2O4S2
  35. The crystal structure of N,N′-(4,4′-oxydibenzyl)-bisisonicotinamide 3.5 hydrate, C24H24N4O6
  36. Crystal structure of catena-poly[hexakis(μ2-chlorido)-hexakis(4-(1H-pyrazol-5-yl)pyridine-κN)tricadmium(II)], Cd3C48H42Cl6N18
  37. Crystal structure of 2-(4-(dimethylamino)phenyl)-1,3-dimethyl-1H-perimidin-3-ium iodide, C21H22I1N3
  38. Crystal structure of 4-(1,3-dimethyl-2,3-dihydro-1H-perimidin-2-yl)benzonitrile, C20H17N3
  39. Crystal structure of tetrakis(μ2-acetato-κ2O:O′)-bis(2,2′-sulfonyldipyrazine-κ1N)dicopper(II), C24H24Cu2N8O12S2
  40. Crystal structure of 1-(4-chlorophenyl)-6,8-diphenyl-1H-pyrazolo[4,3-c]quinoline, C28H18ClN3
  41. Crystal structure of methyl 3-((1-(2-(methoxycarbonyl)benzyl)-1H-1,2,3-triazol-4-yl)methoxy)-2-naphthoate, C24H21N3O5
  42. Crystal structure of (tris(2-pyridylmethyl)amine-κ4N,N′,N′′,N′′′′)-chloranilato-κO,O′-zinc(II) – methanol (1/1), C25H22Cl2N4O5Zn
  43. Crystal structure of 1,1-dimethyl-3-(4-methoxyphenyl)urea, C10H14N2O2
  44. Crystal structure of 4a-Hydroxy-9-(2-nitro-phenyl)-3,4,4a,5,6,7,9,9a-octahydro-2H-xanthene-1,8-dione, C19H19NO6
  45. Crystal structure of chlorido-(η6–1-isopropyl-4-methyl benzene)-(1-(pyridin-2-yl)-N-(p-tolyl)methanimine-κ2N,N′)ruthenium(II) hexafluorophosphate(V), C23H26ClF6N2PRu
  46. Crystal structure of phenyl(2-phenyl-2,3-dihydro-1H-perimidin-2-yl)methanone, C24H18N2O
  47. Crystal structure of (E)-3-methyl-4-((3-(5-methyl-1-phenyl-1H-1,2,3-triazol-4-yl)-1-phenyl-1H-pyrazol-4-yl)methylene)-1-phenyl-1H-pyrazol-5(4H)-one, C29H23N7O
  48. Crystal structure of 2-(4-(2-butyl-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin-6-yl)piperazin-1-yl)-2-oxoethyldiethylcarbamodithioate, C27H34N4O3S2
  49. Crystal structure of poly-[diaqua-bis(μ-4,4′-bipyridine-κ2N:N′)cobalt(II)] bis(4-chlorobenzenesulfonate) – 4,4′-bipyridine – water (1/1/2), C42H40Cl2CoN6O10S2
  50. Crystal structure of (η6-benzene)-(N-(2,6-dimethylphenyl)-1-(pyridin-2-yl)methanimine-κ2N,N′)ruthenium(II) perchlorate monohydrate, C20H20Cl2N2O5Ru
  51. Crystal structure of 4,10,16,22-tetrahydroxy-6,12,18,24-tetramethoxy-2,8,14,20-tetraethylphenylresorcin[4]arene – ethyl acetate (1/1), C68H72O10
  52. Crystal structure of chlorido-(N-(2,5-dichlorophenyl)-1-(pyridin-2-yl)methanimine-κ2N,N′)(η6-1-isopropyl-4-methyl benzene) ruthenium (II) tetrafluoroborate, C22H22Cl3N2BF4Ru
  53. Crystal structure of 3-(5-methyl-1-p-tolyl-1H-1,2,3-triazol-4-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde, a rare Z′ = 3 structure, C20H17N5O
  54. Crystal structure of 5-(5-(4-chlorophenyl)-1-phenyl-1H-pyrazol-3-yl)-N-phenyl-1,3,4-thiadiazol-2-amine, C23H16ClN5S
  55. Crystal structure of 7-hydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one-N,N-dimethylformamide (1/1), C18H17NO5
  56. Crystal structure of halogen-bonded 2-chloro-1,10-phenanthroline—1,4-diiodotetrafluorobenzene (2/1), C30H14Cl2F4I2N4
  57. Crystal structure of 1-(4,4-dimethyl-2,6-dithioxo-1,3,5-triazinan-1-yl)-3-(diethylaminocarbonyl)thiourea, C11H20N6OS3
  58. Crystal structure of methyl 1-(4-fluorobenzyl)-3-phenyl-1H-pyrazole-5-carboxylate, C18H15FN2O2
  59. Crystal structure of 1,1-dimethyl-3-(4-methylphenyl)urea, C10H14N2O
  60. Crystal structure of yttrium gallium antimonide, Y5Ga1.24Sb2.77
  61. Crystal structure of 2-(bis(4-methoxyphenyl)amino)-2-oxoacetic acid, C16H15NO5
Downloaded on 16.12.2025 from https://www.degruyterbrill.com/document/doi/10.1515/ncrs-2016-0235/html?srsltid=AfmBOooD784P6IHcPmhC7hI3nOG8Bnc0tNjt9YDNVzDND7cxQ2sm6JE_
Scroll to top button